Legal status · Australia
Is Ac-SDKP legal in Australia?
No. Ac-SDKP is not an approved medicine in Australia; its classification is "Not approved; Schedule 4 or import-restricted". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. Human evidence: Preliminary.
Ac-SDKP in Australia at a glance
| Classification | Not approved; Schedule 4 or import-restricted |
|---|---|
| TGA approval status | Not approved by TGA |
| Evidence level | Preliminary (research strength: Moderate) |
| Reviewed | Sep 2026 |
Classification and note come from the Ac-SDKP profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.
What this means
- 01
No product containing Ac-SDKP is approved by TGA for any use in Australia, so nothing on the market is authorized for people.
- 02
"Research use only" is a vendor label, not a legal category that permits human use. It does not exempt a product from medicines law.
- 03
Importing, supplying or promoting it for human use can fall under medicines legislation in Australia. This page is general information, not legal advice.
What Ac-SDKP is
The N-terminal four amino acids of thymosin beta-4, a natural anti-fibrotic peptide broken down by ACE (which is why ACE inhibitors raise it); animal and human observational data, sold as capsules unlikely to survive digestion.
Ac-SDKP circulates naturally and limits fibrosis in heart, kidney and lung models. Its blood level rises in people taking ACE inhibitors, a well-documented human observation.
Mechanism: Inhibits fibroblast proliferation and collagen deposition via TGF-beta/Smad signaling; degraded by angiotensin-converting enzyme.
Regulatory history: Not approved
How TGA treats this kind of product
Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.
The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Ac-SDKP at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Ac-SDKP in other countries
Frequently asked questions
Is Ac-SDKP legal in Australia?
No. Ac-SDKP is not an approved medicine in Australia; its classification is "Not approved; Schedule 4 or import-restricted". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. Human evidence: Preliminary.
Can I buy Ac-SDKP in Australia?
No approved product exists to buy. In Australia Ac-SDKP is classified as "Not approved; Schedule 4 or import-restricted", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is Ac-SDKP TGA approved?
No. In Australia Ac-SDKP is classified as "Not approved; Schedule 4 or import-restricted", which is not a TGA marketing approval. For comparison, the US FDA status is: Not approved. Evidence level: Preliminary.
Related compounds in Australia
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Ac-SDKP live on its compound profile.
Ac-SDKP profileThis page is general information about the regulatory status of Ac-SDKP in Australia, current as of Sep 2026. It is not legal advice, and classifications change; check Therapeutic Goods Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.